How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review
Authors
Keywords
-
Journal
Trials
Volume 24, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1186/s13063-023-07730-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
- (2023) Timothée Olivier et al. BMC CANCER
- Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain
- (2021) Celine Yeh et al. SEMINARS IN ONCOLOGY
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J. Page et al. Systematic Reviews
- Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial
- (2021) Supriya Chopra et al. JOURNAL OF CLINICAL ONCOLOGY
- Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
- (2021) Anna-Maria Fontrier et al. Pharmacoeconomics-Open
- A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology
- (2020) Holly Cranmer et al. JOURNAL OF MEDICAL ECONOMICS
- Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
- (2020) Hao Chen et al. Translational Lung Cancer Research
- The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial
- (2019) Carrie Anne Minnaar et al. PLoS One
- Proposals on Kaplan–Meier plots in medical research and a survey of stakeholder views: KMunicate
- (2019) Tim P Morris et al. BMJ Open
- Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
- (2019) Andrew R Clamp et al. LANCET
- Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology
- (2018) Matthieu Texier et al. Computational and Mathematical Methods in Medicine
- First-line treatment in metastatic colorectal cancer: Important or crucial?
- (2017) David Malka et al. EUROPEAN JOURNAL OF CANCER
- Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework
- (2017) Shogo Nomura et al. Journal of Biopharmaceutical Statistics
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Checkpoint inhibition: new treatment options in urologic cancer
- (2017) Daan Joost De Maeseneer et al. ACTA CLINICA BELGICA
- Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting
- (2016) Alona Zer et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details
- (2016) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis
- (2016) Sarah Batson et al. PLoS One
- Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients
- (2016) Anna Miquel-Cases et al. PLoS One
- Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis
- (2015) Emilio Bria et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
- (2015) Ian H Kunkler et al. LANCET ONCOLOGY
- Adaptive truncated weighting for improving marginal structural model estimation of treatment effects informally censored by subsequent therapy
- (2015) Xiaofei Bai et al. PHARMACEUTICAL STATISTICS
- Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
- (2014) Ursula A. Matulonis et al. CANCER
- Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials
- (2014) Xabier García-Albéniz et al. INTERNATIONAL JOURNAL OF CANCER
- Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
- (2014) Ajay Vora et al. LANCET ONCOLOGY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial
- (2013) J. Pénichoux et al. EUROPEAN JOURNAL OF CANCER
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer
- (2013) Martin Hoyle et al. VALUE IN HEALTH
- Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
- (2012) Nicholas D James et al. LANCET ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
- (2011) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09
- (2010) Anthony L. Zietman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search